Immunovant Inc
IMVT15.710USD
-0.370-2.30%
收盘 08/01, 16:00（美东）报价延迟15分钟
2.67B总市值
亏损市盈率 TTM
关于 Immunovant Inc 公司
Immunovant, Inc. 是一家临床阶段免疫学公司。该公司专注于开发自身免疫性疾病患者的治疗方法。其产品线包括巴托利单抗和 IMVT-1402，这两种都是新型的全人源单克隆抗体，靶向新生儿可结晶片段受体 (FcRn)。巴托利单抗是一种皮下注射剂。据观察，巴托利单抗可降低引起炎症和疾病的免疫球蛋白 G (IgG) 抗体。其候选产品巴托利单抗采用小剂量给药，并使用 27 号针头。该公司正在开发用于治疗重症肌无力 (MG)、甲状腺眼病 (TED)、慢性炎症性脱髓鞘性多发性神经病 (CIDP) 和格雷夫斯病 (GD) 的巴托利单抗。其主要候选产品 IMVT-1402 还被观察到在健康成人中进行的 I 期临床试验中可降低 IgG 抗体水平。 IMVT-1402 是一种抑制 FcRn 的完全人源单克隆抗体。
公司简介
公司代码IMVT
公司名称Immunovant Inc
上市日期May 14, 2019
成立日期2018
CEODr. Eric Venker, M.D.
员工数量362
证券类型Ordinary Share
年结日May 14
公司地址320 West 37Th Street
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编10018
电话19175803099
网址https://immunovant.com/
公司代码IMVT
上市日期May 14, 2019
成立日期2018
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
615.44K
-6.15%
Ms. Melanie Gloria
Ms. Melanie Gloria
Chief Operating Officer
Chief Operating Officer
186.14K
+69.28%
Mr. Douglas J. Hughes
Mr. Douglas J. Hughes
Independent Director
Independent Director
119.58K
-3.96%
Dr. Atul Pande, M.D.
Dr. Atul Pande, M.D.
Independent Director
Independent Director
95.41K
-14.51%
Mr. Andrew J. (Drew) Fromkin
Mr. Andrew J. (Drew) Fromkin
Director
Director
91.91K
-5.09%
Dr. Jay S. Stout, Ph.D.
Dr. Jay S. Stout, Ph.D.
Chief Technology Officer
Chief Technology Officer
81.19K
-5.06%
Dr. Michael Geffner, M.D.
Dr. Michael Geffner, M.D.
Chief Medical Officer
Chief Medical Officer
44.95K
-7.31%
Mr. Jacob (Jake) Bauer
Mr. Jacob (Jake) Bauer
Independent Director
Independent Director
--
--
Mr. Robert G. Susman
Mr. Robert G. Susman
Independent Director
Independent Director
--
--
Mr. Tiago Girao
Mr. Tiago Girao
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
615.44K
-6.15%
Ms. Melanie Gloria
Ms. Melanie Gloria
Chief Operating Officer
Chief Operating Officer
186.14K
+69.28%
Mr. Douglas J. Hughes
Mr. Douglas J. Hughes
Independent Director
Independent Director
119.58K
-3.96%
Dr. Atul Pande, M.D.
Dr. Atul Pande, M.D.
Independent Director
Independent Director
95.41K
-14.51%
Mr. Andrew J. (Drew) Fromkin
Mr. Andrew J. (Drew) Fromkin
Director
Director
91.91K
-5.09%
Dr. Jay S. Stout, Ph.D.
Dr. Jay S. Stout, Ph.D.
Chief Technology Officer
Chief Technology Officer
81.19K
-5.06%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Roivant Sciences Ltd.
56.50%
Fidelity Management & Research Company LLC
9.42%
Deep Track Capital LP
5.55%
The Vanguard Group, Inc.
4.04%
T. Rowe Price Investment Management, Inc.
3.45%
Other
21.03%
持股股东
持股股东
占比
Roivant Sciences Ltd.
56.50%
Fidelity Management & Research Company LLC
9.42%
Deep Track Capital LP
5.55%
The Vanguard Group, Inc.
4.04%
T. Rowe Price Investment Management, Inc.
3.45%
Other
21.03%
股东类型
持股股东
占比
Corporation
56.50%
Investment Advisor
27.03%
Hedge Fund
16.91%
Investment Advisor/Hedge Fund
7.34%
Research Firm
1.87%
Individual Investor
1.85%
Private Equity
1.66%
Sovereign Wealth Fund
0.37%
Pension Fund
0.26%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
493
195.12M
114.06%
-1.39M
2025Q1
505
194.81M
114.45%
+16.42M
2024Q4
482
163.29M
104.53%
-8.19M
2024Q3
464
162.18M
111.33%
-1.06M
2024Q2
453
157.67M
108.50%
+1.66M
2024Q1
433
151.47M
104.51%
-605.85K
2023Q4
420
150.13M
103.75%
+991.03K
2023Q3
373
143.75M
105.86%
+4.45M
2023Q2
335
132.11M
101.25%
-11.81M
2023Q1
333
135.44M
104.53%
-12.72M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Roivant Sciences Ltd.
96.65M
56.55%
--
--
Apr 21, 2025
Fidelity Management & Research Company LLC
16.12M
9.43%
+3.86M
+31.52%
Mar 31, 2025
Deep Track Capital LP
9.50M
5.56%
+3.50M
+58.33%
Mar 31, 2025
The Vanguard Group, Inc.
6.92M
4.05%
+251.99K
+3.78%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
5.89M
3.45%
+777.59K
+15.20%
Mar 31, 2025
Baker Bros. Advisors LP
5.46M
3.19%
+3.75M
+219.57%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.75M
2.78%
+191.44K
+4.20%
Mar 31, 2025
Armistice Capital LLC
4.50M
2.63%
+629.41K
+16.26%
Mar 31, 2025
State Street Global Advisors (US)
3.09M
1.81%
+389.57K
+14.44%
Mar 31, 2025
Perceptive Advisors LLC
2.84M
1.66%
+704.87K
+32.95%
Mar 31, 2025
查看更多
持股ETF
更新时间: 14 小时前
更新时间: 14 小时前
机构名称
占比
Tema Neuroscience and Mental Health ETF
0.9%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
SPDR S&P Biotech ETF
0.43%
Invesco Nasdaq Biotechnology ETF
0.3%
ProShares Ultra Nasdaq Biotechnology
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
iShares Biotechnology ETF
0.11%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.07%
iShares Russell 2000 Growth ETF
0.07%
BNY Mellon US Small Cap Core Equity ETF
0.06%
查看更多
Tema Neuroscience and Mental Health ETF
占比0.9%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.9%
SPDR S&P Biotech ETF
占比0.43%
Invesco Nasdaq Biotechnology ETF
占比0.3%
ProShares Ultra Nasdaq Biotechnology
占比0.3%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.25%
iShares Biotechnology ETF
占比0.11%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.07%
iShares Russell 2000 Growth ETF
占比0.07%
BNY Mellon US Small Cap Core Equity ETF
占比0.06%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
